Takeda's Zasocitinib Demonstrates Rapid Skin Clearance in Phase 3 Psoriasis Trials

Takeda's TYK2 inhibitor, zasocitinib, achieved rapid and durable skin clearance in Phase 3 psoriasis trials, with 70% of patients reaching clear or almost clear skin by week 16. The drug showed a significant PASI 75 response rate as early as week 4. Takeda plans to submit a New Drug Application to the FDA and other regulatory authorities in FY2026.